LifeSci Capital analyst Francois Brisebois has maintained their bullish stance on KALA stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Francois Brisebois has given his Buy rating due to a combination of factors that highlight Kala Pharmaceuticals’ strategic positioning and potential for success. The upcoming Phase 2b trial for KPI-012, targeting Persistent Corneal Epithelial Defect (PCED), is a significant focus. The trial’s unique run-in design is expected to reduce the placebo effect, which could enhance the statistical significance of the results. This approach is crucial given the unmet need in the PCED market, aligning with the efficacy seen in previous trials like Oxervate.
Brisebois also notes the trial’s robust design, with an increased sample size and adjusted dosing, which could lead to a more accurate assessment of KPI-012’s efficacy. The potential for superior efficacy compared to existing treatments like Oxervate could allow Kala Pharmaceuticals to capture a larger market share, particularly in the established NK market. These factors, combined with the company’s strategic adjustments and the potential for significant stock appreciation, underpin Brisebois’s Buy rating for Kala Pharmaceuticals.
Brisebois covers the Healthcare sector, focusing on stocks such as Kala Pharmaceuticals, Avadel Pharmaceuticals, and Centessa Pharmaceuticals. According to TipRanks, Brisebois has an average return of -3.6% and a 37.19% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.